Literature DB >> 35440715

Cancer treatments should benefit patients: a common-sense revolution in oncology.

Bishal Gyawali1,2, Christopher M Booth3,4.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35440715     DOI： 10.1038/s41591-021-01662-6

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   87.241


× No keyword cloud information.
  19 in total

1.  The Use of Superlatives in Cancer Research.

Authors:  Matthew V Abola; Vinay Prasad
Journal:  JAMA Oncol       Date:  2016-01       Impact factor: 31.777

2.  Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks.

Authors:  Joseph C Del Paggio; Richard Sullivan; Deborah Schrag; Wilma M Hopman; Biju Azariah; C S Pramesh; Ian F Tannock; Christopher M Booth
Journal:  Lancet Oncol       Date:  2017-06-02       Impact factor: 41.316

3.  Industry Funding of Cancer Patient Advocacy Organizations.

Authors:  Matthew V Abola; Vinay Prasad
Journal:  Mayo Clin Proc       Date:  2016-11       Impact factor: 7.616

Review 4.  Real-world data: towards achieving the achievable in cancer care.

Authors:  Christopher M Booth; Safiya Karim; William J Mackillop
Journal:  Nat Rev Clin Oncol       Date:  2019-05       Impact factor: 66.675

5.  Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?

Authors:  J C Del Paggio; B Azariah; R Sullivan; W M Hopman; F V James; S Roshni; I F Tannock; C M Booth
Journal:  Ann Oncol       Date:  2017-01-01       Impact factor: 32.976

6.  Cancer groundshot: going global before going to the moon.

Authors:  Bishal Gyawali; Richard Sullivan; Christopher M Booth
Journal:  Lancet Oncol       Date:  2018-03       Impact factor: 41.316

7.  Real-world evidence and regulatory drug approval.

Authors:  Michael J Raphael; Bishal Gyawali; Christopher M Booth
Journal:  Nat Rev Clin Oncol       Date:  2020-05       Impact factor: 66.675

8.  Challenges and opportunities for cancer clinical trials in low- and middle-income countries.

Authors:  Bishal Gyawali; Gauthier Bouche; Nigel Crisp; Nicolas André
Journal:  Nat Cancer       Date:  2020-02

9.  Evolution of the Randomized Clinical Trial in the Era of Precision Oncology.

Authors:  Joseph C Del Paggio; John S Berry; Wilma M Hopman; Elizabeth A Eisenhauer; Vinay Prasad; Bishal Gyawali; Christopher M Booth
Journal:  JAMA Oncol       Date:  2021-05-01       Impact factor: 31.777

Review 10.  Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring.

Authors:  B Gyawali; E G E de Vries; U Dafni; T Amaral; J Barriuso; J Bogaerts; A Calles; G Curigliano; C Gomez-Roca; B Kiesewetter; S Oosting; A Passaro; G Pentheroudakis; M Piccart; F Roitberg; J Tabernero; N Tarazona; D Trapani; R Wester; G Zarkavelis; C Zielinski; P Zygoura; N I Cherny
Journal:  ESMO Open       Date:  2021-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.